Radiotherapy Center Cluj S.R.L.
- Address
- lock Available on a paid plan
Analytical, Diagnostic and Therapeutic Techniques and Equipment – Therapeutics
The Radiotherapy Center Cluj S.R.L. leverages cutting‑edge imaging and radiotherapy devices to evaluate novel therapeutic technologies for solid tumors, aiming to improve treatment precision and patient safety.
- Safety and tolerability of new drug combinations
- Assessment of novel radiotherapy delivery methods
- Integration of diagnostic biomarkers with therapy decisions
With 11 investigators overseeing 70 active studies, the site emphasizes rapid translation of innovative equipment into clinical benefit.
Digestive System Diseases
Clinical research at the center targets cancers of the stomach, esophagus, pancreas and biliary tract, seeking to enhance outcomes with targeted and immuno‑oncology approaches.
- Advanced gastric adenocarcinoma
- HER2‑negative, CLDN18.2‑positive gastroesophageal junction cancer
- Esophageal squamous cell carcinoma
- Cholangiocarcinoma
- Pancreatic ductal adenocarcinoma
Trials frequently combine checkpoint inhibitors with chemotherapy to test whether newer regimens can extend survival in these hard‑to‑treat diseases.
Neoplasms
The oncology department conducts a broad spectrum of studies on solid tumors, focusing on immunotherapy and targeted agents to improve cure rates across cancer types.
- Advanced melanoma
- HER2‑positive metastatic breast cancer
- High‑risk early‑stage breast cancer
- Advanced ovarian cancer
- Renal cell carcinoma
- Head and neck squamous cell carcinoma
Many protocols explore adjuvant or maintenance strategies after surgery or radiotherapy, aiming to reduce recurrence.
Respiratory Tract Diseases
A substantial portion of the research portfolio addresses lung malignancies, with a goal to identify more effective systemic and local therapies for patients with advanced disease.
- Advanced non‑small cell lung cancer (NSCLC)
- KRAS G12C‑mutant NSCLC
- ROS1‑rearranged NSCLC
- Extensive‑stage small cell lung cancer (SCLC)
- Metastatic squamous NSCLC
Studies often pair novel inhibitors with checkpoint blockade and incorporate radiotherapy to assess synergistic effects.
Miscellaneous / Not Specified
In addition to disease‑focused trials, the center runs platform and exploratory studies that investigate emerging biomarkers and multi‑agent combos across diverse solid tumors.
- Solid tumors of unknown primary origin
- Rare sarcoma subtypes
- Antibody‑drug conjugates in heterogeneous cancers
- Safety profiling of first‑in‑human agents
- Biomarker‑driven adaptive trial designs
These flexible investigations allow rapid assessment of promising therapies that may later enter disease‑specific programs.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 128 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 127 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 25 by active trials.
lock +24 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC25trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Radiotherapy Center Cluj S.R.L.
lock Showing 1 of 98 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of FYB206 and Pembrolizumab in Metastatic Non-Squamous NSCLC | Formycon AG | Phase III | Not Recruiting | — | Feb 2025 |
IMP list
lock Showing 1 of 128 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 41 | Unknown | 2018-03-21 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.